March 2, 2015
The Pharmaceuticals and Medical Devices Agency (PMDA) announced on February 27 that the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin phosphate hydrate (MSD K.K.’s Januvia and Ono Pharmaceutical’s Glactiv) is being evaluated for the risk of thrombocytopenia. Other evaluations include, 1) rebamipide...read more